Mabpharm Limited (02181) Publishes Monthly Return for November 2025

Bulletin Express

Dec 03, 2025

Mabpharm Limited (02181) reported that its total authorized share capital remained at 50,000,000,000 ordinary shares as of November 30, 2025, carrying a par value of USD 0.0001 each, for a total of USD 5,000,000. The issued share capital stood unchanged from the previous month, with 4,124,080,000 ordinary shares in issue and no treasury shares reported.

The share option scheme, previously approved on August 10, 2018, maintained 72,670,876 outstanding share options with no new issuances or exercises during the period. The company indicated no movement in warrants, convertibles, or other share issuance arrangements during November 2025. The disclosure was submitted by Secretary Tsang Ho Yin on December 3, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1156374522"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156374522\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156374522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 16:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156374522","market":"hk","top_or_hot":-1,"title":"Mabpharm Limited (02181) Publishes Monthly Return for November 2025","media":"Bulletin Express","content":"<p>Mabpharm Limited (02181) reported that its total authorized share capital remained at 50,000,000,000 ordinary shares as of November 30, 2025, carrying a par value of USD 0.0001 each, for a total of USD 5,000,000. The issued share capital stood unchanged from the previous month, with 4,124,080,000 ordinary shares in issue and no treasury shares reported.</p>\n<p>The share option scheme, previously approved on August 10, 2018, maintained 72,670,876 outstanding share options with no new issuances or exercises during the period. The company indicated no movement in warrants, convertibles, or other share issuance arrangements during November 2025. The disclosure was submitted by Secretary Tsang Ho Yin on December 3, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabpharm Limited (02181) Publishes Monthly Return for November 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabpharm Limited (02181) Publishes Monthly Return for November 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-03 16:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabpharm Limited (02181) reported that its total authorized share capital remained at 50,000,000,000 ordinary shares as of November 30, 2025, carrying a par value of USD 0.0001 each, for a total of USD 5,000,000. The issued share capital stood unchanged from the previous month, with 4,124,080,000 ordinary shares in issue and no treasury shares reported.</p>\n<p>The share option scheme, previously approved on August 10, 2018, maintained 72,670,876 outstanding share options with no new issuances or exercises during the period. The company indicated no movement in warrants, convertibles, or other share issuance arrangements during November 2025. The disclosure was submitted by Secretary Tsang Ho Yin on December 3, 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02181","symbol_name":"迈博药业-B","start_time":0,"source_url":"","article_id":"1156374522","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156374522","pubTimestamp":1764751767,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Mabpharm Limited (02181) reported that its total authorized share capital remained at 50,000,000,000 ordinary shares as of November 30, 2025, carrying a par value of USD 0.0001 each, for a total of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02181":"迈博药业-B"},"translate_title":"迈博药业(02181)公布2025年11月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02181":1},"content_text":"Mabpharm Limited (02181) reported that its total authorized share capital remained at 50,000,000,000 ordinary shares as of November 30, 2025, carrying a par value of USD 0.0001 each, for a total of USD 5,000,000. The issued share capital stood unchanged from the previous month, with 4,124,080,000 ordinary shares in issue and no treasury shares reported.\nThe share option scheme, previously approved on August 10, 2018, maintained 72,670,876 outstanding share options with no new issuances or exercises during the period. The company indicated no movement in warrants, convertibles, or other share issuance arrangements during November 2025. The disclosure was submitted by Secretary Tsang Ho Yin on December 3, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}